MX2019008076A - Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. - Google Patents
Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.Info
- Publication number
- MX2019008076A MX2019008076A MX2019008076A MX2019008076A MX2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A
- Authority
- MX
- Mexico
- Prior art keywords
- galactosidase
- fabry
- treatment
- therapeutic regimen
- alpha
- Prior art date
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 title abstract 3
- 108010030291 alpha-Galactosidase Proteins 0.000 title abstract 3
- 238000011285 therapeutic regimen Methods 0.000 title 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762442537P | 2017-01-05 | 2017-01-05 | |
| PCT/IL2018/050018 WO2018127920A1 (en) | 2017-01-05 | 2018-01-05 | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008076A true MX2019008076A (es) | 2019-08-29 |
Family
ID=62790830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008076A MX2019008076A (es) | 2017-01-05 | 2018-01-05 | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12194079B2 (https=) |
| EP (1) | EP3565583A4 (https=) |
| JP (2) | JP2020504131A (https=) |
| KR (2) | KR20240042110A (https=) |
| CN (2) | CN117959455A (https=) |
| AU (1) | AU2018205891B2 (https=) |
| BR (1) | BR112019013920A2 (https=) |
| CA (1) | CA3048151A1 (https=) |
| CL (1) | CL2019001867A1 (https=) |
| IL (1) | IL267863A (https=) |
| MX (1) | MX2019008076A (https=) |
| NZ (1) | NZ755725A (https=) |
| WO (1) | WO2018127920A1 (https=) |
| ZA (1) | ZA201904850B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| MX2021015352A (es) * | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| US20230416714A1 (en) * | 2020-11-13 | 2023-12-28 | Hanmi Pharm. Co., Ltd | Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease |
| AU2021378707A1 (en) * | 2020-11-13 | 2023-06-01 | Hanmi Pharm. Co., Ltd. | Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by Fabry disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| DK1503788T3 (da) * | 2002-04-25 | 2011-10-17 | Shire Human Genetic Therapies | Behandling af alpha-galactosidase A-deficiens |
| EP1877099B1 (en) | 2005-04-06 | 2012-09-19 | Genzyme Corporation | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| CA2696699A1 (en) | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| US9194011B2 (en) * | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
| SI2865751T1 (sl) | 2010-03-02 | 2017-01-31 | Protalix Ltd. | Stabilizirana alfa-galaktozidaza in njene uporabe |
| KR101883803B1 (ko) | 2011-01-20 | 2018-07-31 | 프로탈릭스 리미티드 | 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물 |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
-
2018
- 2018-01-05 WO PCT/IL2018/050018 patent/WO2018127920A1/en not_active Ceased
- 2018-01-05 US US16/476,084 patent/US12194079B2/en active Active
- 2018-01-05 NZ NZ755725A patent/NZ755725A/en unknown
- 2018-01-05 MX MX2019008076A patent/MX2019008076A/es unknown
- 2018-01-05 EP EP18736643.0A patent/EP3565583A4/en active Pending
- 2018-01-05 KR KR1020247008410A patent/KR20240042110A/ko not_active Ceased
- 2018-01-05 AU AU2018205891A patent/AU2018205891B2/en active Active
- 2018-01-05 BR BR112019013920A patent/BR112019013920A2/pt unknown
- 2018-01-05 CA CA3048151A patent/CA3048151A1/en active Pending
- 2018-01-05 CN CN202410140178.XA patent/CN117959455A/zh active Pending
- 2018-01-05 CN CN201880016068.5A patent/CN110381987A/zh active Pending
- 2018-01-05 JP JP2019536488A patent/JP2020504131A/ja active Pending
- 2018-01-05 KR KR1020197023039A patent/KR20190103320A/ko not_active Ceased
-
2019
- 2019-07-04 CL CL2019001867A patent/CL2019001867A1/es unknown
- 2019-07-04 IL IL267863A patent/IL267863A/en unknown
- 2019-07-24 ZA ZA2019/04850A patent/ZA201904850B/en unknown
-
2022
- 2022-12-01 JP JP2022192939A patent/JP2023022244A/ja active Pending
-
2025
- 2025-01-10 US US19/015,746 patent/US20250134968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190103320A (ko) | 2019-09-04 |
| EP3565583A4 (en) | 2020-12-02 |
| BR112019013920A2 (pt) | 2020-02-04 |
| NZ755725A (en) | 2023-06-30 |
| CA3048151A1 (en) | 2018-07-12 |
| CL2019001867A1 (es) | 2019-10-04 |
| CN110381987A (zh) | 2019-10-25 |
| RU2019124280A (ru) | 2021-02-06 |
| KR20240042110A (ko) | 2024-04-01 |
| US20250134968A1 (en) | 2025-05-01 |
| AU2018205891A1 (en) | 2019-08-15 |
| AU2018205891B2 (en) | 2024-11-07 |
| JP2023022244A (ja) | 2023-02-14 |
| IL267863A (en) | 2019-09-26 |
| WO2018127920A1 (en) | 2018-07-12 |
| US20200155654A1 (en) | 2020-05-21 |
| US12194079B2 (en) | 2025-01-14 |
| RU2019124280A3 (https=) | 2021-09-14 |
| CN117959455A (zh) | 2024-05-03 |
| ZA201904850B (en) | 2022-04-28 |
| JP2020504131A (ja) | 2020-02-06 |
| EP3565583A1 (en) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Perez et al. | Update on the use of immunoglobulin in human disease: a review of evidence | |
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| MX2019008076A (es) | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. | |
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| MX2010004508A (es) | Suministro de agentes activos. | |
| MX2023012271A (es) | Medicina terapeutica para enfermedades fibrosas. | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| EP4523745A3 (en) | Bis-choline tetrathiomolybdate for treating wilson disease | |
| AU2020231505A8 (en) | Sequential intravitreal administration of AAV gene therapy to contralateral eyes | |
| WO2019157056A8 (en) | Treatment of patients with classic fabry disease | |
| MX2009003532A (es) | Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| WO2021007314A3 (en) | Treatment of cancer | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| WO2001080895A3 (en) | Methods and compositions for the treatment of cardiac indications | |
| EP4327869A3 (en) | Methods of treating fabry patients having renal impairment | |
| MX2021002090A (es) | Metodos para reducir el riesgo de diabetes en pacientes que son tratados por enfermedades relacionadas con el colesterol alto. | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность |